Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study

Infectious Agents and Cancer

G Hossein Ashrafi²  Ahmad Shykhpour¹  Omid Emadeian³  Alireza Rafiei¹  Tahereh Golini-moghaddam³  Mohammadreza Haghshenas¹ 

[1] Molecular and Cell Biology Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran;SEC Faculty, Penrhyn Road, Kingston University London, Kingston upon Thames, UK KT1 2EE;Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran

关键词: PCR;    Genotype of HPV;    Cervical cancer;    Human papillomavirus;   

Others  :  803031
DOI  :  10.1186/1750-9378-8-20

 received in 2013-03-19, accepted in 2013-06-03,  发布年份 2013

【 摘 要 】

Background

Cervical cancer is the greater cause of cancer death in women in many developing countries. Persistent infection with human papilloma virus (HPV), primarily high risk types 16 and 18, is recognized as a causal and essential factor for the development of cervical cancer. We aimed to determine the distribution of high-risk HPV genotypes in archival biopsies with cervical carcinoma in patients from Mazandaran Province, Northern Iran.

Methods

A total of 98 paraffin-embedded cervical samples consisted of 63 Squamous Cell Carcinomas (SCC), 4 Adenocarcinomas, 19 Cervical Interaepithelial Neoplasia grade I (CIN-I), 4 CIN-II and 8 CIN-III diagnosed during 2009–2011, were selected to perform high risk HPV genotyping using AmpliSens^(R) HPV HCR DNA genotyping kit. The prevalence of HPV infections was assessed in low and high grade cervical lesions by age.

Results

Of the 98 cervical samples analysed by DNA PCR, 78 (79.59%) were positive for HPV DNA. HPV was detected in the 52 of SCC, 4 of Adenocarcinomas, 14 of CIN-I, 4 of CIN-II, and 4 of CIN-III for HPV. From the 78 HPV positive samples, 23 (29.5%) samples were positive for HPV type 16, 32 (41%) were positive for HPV 18, 19 (24.4%) were positive for HPV 45, and 4 (5.1%) of cervical specimens were positive for HPV 39.

Conclusions

This study provides valuable baseline data for future assessment of the impact of current prophylactic vaccination programs that is protective against the two most common oncogenic types of HPV found in cervical cancer, HPV-16 and HPV-18, but not against other high-risk mucosal HPVs, 39 and 45, reported in this population.

【 授权许可】

   
2013 Haghshenas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-84.
• [2]Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007, 7:11-22.
• [3]Boffetta P, Parkin DM: Cancer in developing countries. CA Cancer J Clin 1994, 44:81-90.
• [4]Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ: Human papillomavirus: the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996, 65:601-606.
• [5]Lanham S, Herbert A, Basarab A, Watt P: Detection of Cervical Infections in Colposcopy Clinic Patients. J Clin Microbiol 2001, 39:2946-2950.
• [6]Moberg M, Gustavsson I, Gyllensten U: Real-Time PCR Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer. J Clin Microbiol 2003, 41:3221-3228.
• [7]Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H: Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33, and 45 in the Majority of Cervical Carcinomas. J Clin Microbiol 2006, 2006(44):1310-1317.
• [8]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [9]Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [10]Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003, 162:747-53.
• [11]Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG: Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001, 92:2875-84.
• [12]Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
• [13]Munoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19:1-5.
• [14]Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
• [15]Munoz N, Bosch FX, De Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N: The causal link between human papillomavirus and invasive cervical cancer: a population-based case–control study in Colombia and Spain. Int J Cancer 1992, 52:743-9.
• [16]Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C: Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010, 19:2389-2400.
• [17]Siegler E, Lahat N, Shiner M, Mackuli L, Aroudi Y, Shapiro S, Auslander R, Lavie O: Human papillomavirus types in women with cervical cancer in Haifa District. Harefuah 2011, 150:837-41, 876.
• [18]Gudleviciene Z, Didziapetriene J, Suziedelis K, Lapkauskaite L: Investigation of human papillomavirus, its types and variants. Medicina (Kaunas) 2005, 41:910-5.
• [19]Liu J, Rose B, Huang X, Liao G, Carter J, Wu X, Thompson C: Comparative analysis of characteristics of women with cervical cancer in high- versus low-incidence regions. Gynecol Oncol 2004, 94:803-10.
• [20]Sowjanya AP, Jain M, Poli UR, Padma S, Das M, Shah KV: Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 2005, 5:116. BioMed Central Full Text
• [21]Qiu AD, Wu EQ, Yu XH, Jiang CL, Jin YH, Wu YG, Chen Y, Chen Y, Shan YM, Zhang GN, Fan Y, Zha X, Kong W: HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China. Gynecol Oncol 2007, 2007(104):77-85.
• [22]Dursun P, Senger SS, Arslan H, Kus¸çu E, Ayhan A: Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis 2009, 191:1-6.
• [23]Munoz N, Bosch FX, Castellsague X, Diaz M, De Sanjose S, Hammouda D: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-85.
• [24]Bosch FX, Burchell AN, Schiffman M, Giuliano AR, De Sanjose S, Bruni L: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 10:1-16.
• [25]Eslami G, Golshani M, Rakhshan M, Fallah F, Goudarzi H, Taghavi A: PCR detection and high risk typing of human papillomavirus DNA in cervical cancer in Iranian women. Cancer Therapy 2008, 6:361-366.
• [26]Niakan M, Yarandi F, Entezar M: Human papillomavirus (HPV) detection in biopsies from cervical cancer patients; A population–based study from Iran. Iran J Clin Infect Dis 2009, 4:35-37.
• [27]Mortazavi S, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A: The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev 2002, 3(1):69-72.
• [28]Pirog EC, Kleter B, Olgac S: Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000, 157:1055-1062.
• [29]WHO⁄ ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human papillomavirus and related cancers in Senegal. 2010. [Summary report update] http://www.who.int/hpvcentre webcite